Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Oligodendroglioma 1Glioma 1Glioblastoma 1Astrocytoma 1

Interventions

Temozolomide 5Specimen Handling 2Radiotherapy 2Magnetic Resonance Spectroscopy 2vorasidenib 1vocimagene amiretrorepvec 1trametinib 1pembrolizumab 1dabrafenib 1abexinostat 1Vorinostat 1Transurethral Resection of Bladder 1Surgical Procedures, Operative 1Standard of Care 1Spinal Puncture 1Restraint, Physical 1Radiotherapy, Intensity-Modulated 1Radiation 1Protons 1Proton Therapy 1Practice Guidelines as Topic 1Outcome Assessment, Health Care 1Observational Studies as Topic 1Ketoconazole 1Irinotecan 1Heart Rate 1Granulocyte-Macrophage Colony-Stimulating Factor 1Eflornithine 1Diphtheria-Tetanus Vaccine 1DNA 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Oligodendroglioma × vocimagene amiretrorepvec × 90 days × Clear all
NCT04105374 2026-05-07

Testing the Addition of an Anti-cancer Viral Gene Therapy, Toca 511/Toca FC, to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed Glioblastoma

NRG Oncology

Phase 2/3 Withdrawn
CNS

Astrocytoma, Glioblastoma, Oligodendroglioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡